| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management
|
Luxi, Nicoletta
|
|
|
36 |
4 |
p. 443-458
|
artikel
|
| 2 |
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy
|
Booth, Mary E.
|
|
|
36 |
4 |
p. 487
|
artikel
|
| 3 |
Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy
|
Booth, Mary E.
|
|
|
36 |
4 |
p. 473-485
|
artikel
|
| 4 |
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One
|
Park, Joseph P.
|
|
|
36 |
4 |
p. 431-436
|
artikel
|
| 5 |
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis
|
Abadie, Bryan Q.
|
|
|
36 |
4 |
p. 459-472
|
artikel
|
| 6 |
Pharmacists’ Perspectives of Biosimilars: A Systematic Review
|
Mohd Sani, Noraisyah
|
|
|
36 |
4 |
p. 489-508
|
artikel
|
| 7 |
Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records
|
Jin, Yinzhu
|
|
|
36 |
4 |
p. 521-535
|
artikel
|
| 8 |
Progress with RNA Interference for the Treatment of Primary Hyperoxaluria
|
Sawyer, Kathryn
|
|
|
36 |
4 |
p. 437-441
|
artikel
|
| 9 |
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
|
Luukkanen, Saana V.
|
|
|
36 |
4 |
p. 537-547
|
artikel
|
| 10 |
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (VigilVacCOVID Study)
|
Sáez-Peñataro, Joaquín
|
|
|
36 |
4 |
p. 509-520
|
artikel
|
Tijdschrift beschrijving